President Donald Trump rescinded an executive order issued by former President Joe Biden aimed at finding new models for lowering drug costs. Trump's action didn't affect the caps on seniors' drug costs or Medicare price negotiations that Biden signed into law.

January, the Biden administration released its proposed Medicare Advantage rates in 2026. These are the rates that the government pays insurers for the program to provide low-cost, affordable plans for seniors.

Reforms of prescription drug pricing are finally taking full effect, just in time for Donald Trump and the Republicans to wreck them.

“Today, I’m proud to announce that my Administration has selected the next 15 drugs for Medicare drug price negotiation. The drugs treat conditions such as diabetes and cancer, and seniors across the country rely on them,” President Joe Biden said in ...

to develop and test ways to lower drug prices for people on Medicare and Medicaid. Since former-President Joe Biden's 2022 order, CMS had been planning out and preparing to test three models to lower prices. None of them had fully gone into effect.

The executive order, which Biden signed in October 2022, had not spurred any lower drug prices by the time Trump revoked it Jan. 20. The order directed the Health and Human Services Department secretary to consider "new health care payment and delivery models" for the Center for Medicare and Medicaid Innovation to test.

Biden's administration announced weight loss drugs Ozempic and Wegovy will be included on Medicare's list of medications subject to direct price negotiations.

Diabetes and weight loss drugs Ozempic and Wegovy have been added to the list of medications selected for Medicare price negotiations, federal health officials announced Friday. The negotiations for the 15 additional drugs, which will be handled by the incoming administration, assure major savings for Americans.

The Biden administration says popular weight loss drugs like Ozempic and Wegovy have been added to Medicare’s list of medications that will be negotiated directly between the government and drug manufacturers.

President Trump is rolling back Biden healthcare policies, such as expansions to the Affordable Care Act – a move Democrats described as an "attack" on the federal program.

Experts suggest that most Americans will not experience immediate changes in their out-of-pocket health care expenses.

The Trump administration’s first drug pricing action — rescinding a Biden executive order encouraging Medicare to help lower prescription costs — is befuddling drug pricing experts.